WCN26-1861 ATRASENTAN VS PLACEBO IN SUBGROUPS OF PATIENTS FROM EAST ASIA WITH IgA NEPHROPATHY (IgAN): INTERIM DATA FROM THE PHASE III ALIGN TRIAL

Authors: Hiddo J.L. Heerspink, Meg J. Jardine, Donald E. Kohan et al.
Publication: Kidney International Reports
Published: Apr 1, 2026
Source: Crossref
Back to Search View Original Cite This Article

Related Articles

Efficacy of combined Eschscholtzia californica Cham. and Valeriana officinalis L. extracts in alleviating insomnia associated with anxiety: A randomized, double-blind, placebo-controlled trial

Samira Ait Abdellah, Claude Blondeau et al. - Dec 2026

Read More
Effect of diamine oxidase (DAO) enzyme dietary supplementation in subjects with insomnia symptoms and single nucleotide polymorphisms of the AOC1 gene: a randomized double-blind placebo-controlled study

Júlia Ferrer-Garcia, Maria D. Navarro et al. - Dec 2026

Read More
Associations between placebo-responses across models and time: Exploratory analysis of a sham randomized clinical trial in chronic-back-pain patients

Adi Shani, Rima Ghanayim et al. - Jul 2026

Read More
Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial

S. David Miller, Craig F. LaForce et al. - Jun 2026

Read More
Aurantii Fructus Immaturus flavonoid tablets for functional dyspepsia: A randomized, placebo-controlled phase IIa trial

Ke Ma, Qin Wan et al. - Jun 2026

Read More